I
INTENSITY THERAPEUTICS, INC.
INTSCIK 0001567264NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-11.60M
Total Assets
$14.10M
Equity
$11.88M
Shares Out
2.54M
Op. Cash Flow
$-9.23M
Business
INTENSITY THERAPEUTICS, INC. is a clinical-stage biotechnology company developing localized intratumoral cancer therapies using its proprietary DfuseRx platform to enable drug dispersion and immune activation. Its main product candidates are amphiphilic formulations that combine established cytotoxic agents with a penetration-enhancing molecule, with lead candidate INT230-6 comprised of cisplatin, vinblastine sulfate and the SHAO diffusion enhancer. The company’s activities focus on clinical development programs and collaborations, including Phase 3 and Phase 2 studies and research partnerships with academic and industry sponsors. It conducts multi‑country clinical trials and outsources manufacturing and clinical operations through contract manufacturing organizations, CROs and academic networks for distribution to hospitals and treatment centers.
Summary from filing dated 2025-03-13
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 7 | 10 | 5 | 5 | |
| General and administrative | 5 | 6 | 4 | 2 | |
| Total operating expenses | 12 | 17 | 8 | 8 | |
| Loss from operations | −12 | −17 | −8 | −8 | |
| Interest income | 180,000 | 314,000 | 324,000 | 2,000 | |
| Other income, net | 186,000 | 3,000 | — | — | |
| Net loss | −12 | −16 | −11 | −8 | |
| Loss per share, basic (in dollars per share) | −8.56 | −29.24 | −1.38 | −2.22 | |
| Loss per share, diluted (in dollars per share) | −8.56 | −29.24 | −1.38 | −2.22 | |
| Weighted average number of shares of common stock, basic (in shares) | 1 | 556,279 | 9 | 3 | |
| Weighted average number of shares of common stock, diluted (in shares) | 1 | 556,279 | 9 | 3 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12 | 3 | 9 | 1 | — | |
| Prepaid expenses and other current assets | 788,000 | 773,000 | 688,000 | — | — | |
| Total current assets | 13 | 3 | 15 | 1 | — | |
| Right-of-use asset, net | 96,000 | 122,000 | 147,000 | 139,000 | — | |
| Other assets | 1 | 1 | 2 | 167,000 | — | |
| Total assets | 14 | 5 | 17 | 2 | — | |
| Accounts payable | 583,000 | 1 | 3 | 603,000 | — | |
| Accrued expenses | 2 | 508,000 | 891,000 | 2 | — | |
| Lease liability, current portion | 31,000 | 28,000 | 20,000 | 143,000 | — | |
| Total current liabilities | 2 | 2 | 4 | 7 | — | |
| Lease liability, net of long-term portion | 79,000 | 110,000 | 138,000 | 0 | — | |
| Total liabilities | 2 | 2 | 4 | 7 | — | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, par value $.0001. Authorized shares of 15,000,000 as of both December 31, 2025 and 2024, respectively. None issued and outstanding as of both December 31, 2025 and 2024. | 0 | 0 | 0 | 0 | — | |
| Common stock, par value $.0001. Authorized shares of 135,000,000 as of both December 31, 2025 and 2024, respectively. Issued and outstanding shares of 2,524,475 and 604,915 as of December 31, 2025 and 2024, respectively. | 0 | 0 | 1,000 | 0 | — | |
| Additional paid-in capital | 90 | 70 | 64 | 24 | — | |
| Accumulated deficit | −78 | −67 | −51 | −39 | — | |
| Total stockholders equity | 12 | 3 | 13 | −15 | −9 | |
| Total liabilities and stockholders equity | 14 | 5 | 17 | 2 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Change in carrying value of right-of-use asset | 26,000 | 25,000 | 147,000 | 179,000 | |
| Stock-based compensation expense | 2 | 3 | 1 | 1 | |
| Stock issued in exchange for services | 0 | 51,000 | 0 | — | |
| Accrued interest on marketable debt securities | 0 | −134,000 | −197,000 | 0 | |
| Prepaid expenses, other current assets, and other assets | −13,000 | 301,000 | −2 | 53,000 | |
| Accounts payable, accrued expenses and other liabilities | 360,000 | −2 | 2 | 704,000 | |
| Net cash used in operating activities | −9 | −15 | −7 | −5 | |
| Purchase of marketable debt securities | 0 | −3 | −15 | 0 | |
| Redemption of marketable debt securities | 0 | 9 | 9 | 0 | |
| Net cash provided by investing activities | 0 | 6 | −6 | 0 | |
| Proceeds from Public Offerings | 5 | 0 | 22 | 0 | |
| Proceeds from exercise of options and warrants | 56,000 | 321,000 | 50,000 | 0 | |
| Net cash provided by financing activities | 19 | 3 | 20 | 2 | |
| Net increase (decrease) in cash and cash equivalents | 9 | −6 | 7 | −3 | |
| Common stock issued in exchange for services | 0 | 51,000 | 5 | 0 | |
| Warrants issued to underwriter in connection with stock issuance | 1 | 1 | 1 | 0 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro